Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  Issue: May 2019  |  May 17, 2019

  • Fatal hepatosplenic T cell lymphoma (HSTCL) has occurred postmarketing in adolescent and young adult inflammatory bowel disease (IBD) patients treated with TNFi’s.

Warnings & Precautions

  • Do not start adalimumab during an active infection. If an infection develops, monitor carefully, and stop adalimumab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on adalimumab, consider empiric anti-fungal therapy for those who reside in or travel to regions where mycoses are endemic.
  • The incidence of malignancies was greater in adalimumab-treated patients than in the control groups.
  • Anaphylaxis or serious allergic reactions may occur.
  • Hepatitis B virus (HBV) reactivation can occur. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop adalimumab and begin anti-viral therapy.
  • Demyelinating disease exacerbation, or new onset, may occur.
  • Cytopenias, pancytopenia—advise patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on adalimumab. Consider discontinuation of therapy in patients with confirmed significant hematologic abnormalities.
  • Heart failure, worsening or new onset, may occur.
  • Lupus-like syndrome—stop adalimumab if syndrome develops.

Dosage & Administration

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Adalimumab is administered by subcutaneous injection. The recommended dose is an initial dose of 80 mg, followed by 40 mg every other week starting one week after the initial dose.

Commentary: The approval of adalimumab for plaque psoriasis was based on two pivotal clinical trials that had enrolled more than 1,400 patients. Nearly three in four patients achieved at least a PASI 75 at Week 16 of treatment vs. placebo. The most common adverse reactions (≥10%) are infections (e.g., upper respiratory, sinusitis), injection-site reactions, headache and rash.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Certolizumab pegol (Cimzia):14 injection

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (above)

Warnings & Precautions

  • Do not start certolizumab during an active infection. If an infection develops, monitor carefully, and stop certolizumab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on certolizumab, consider empiric anti-fungal therapy for those who reside in or travel to regions where mycoses are endemic.
  • Cases of lymphoma and other malignancies have been observed in patients receiving TNFi’s.
  • Heart failure, worsening or new onset, may occur.
  • Anaphylaxis or serious allergic reactions may occur.
  • HBV reactivation can occur. Test for HBV infection before starting certolizumab. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop certolizumab and begin anti-viral therapy.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Cytopenias, pancytopenia—advise patients to seek immediate medical attention if symptoms develop, and consider stopping certolizumab.
  • Lupus-like syndrome—stop certolizumab if syndrome develops.

Dosage & Administration

Certolizumab is administered by sub­cutaneous injection. The recommended initial dose is 400 mg (given as two subcutaneous injections of 200 mg) every other week. For some patients (with body weight ≤90 kg), a dose of 400 mg (given as two subcutaneous injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg every other week may be considered.

Commentary: The U.S. Food and Drug Administration (FDA) approval was based on three clinical trials that enrolled over 1,000 patients. The results showed that patients had significant improvement in psoriasis symptoms through Week 48 in adults who received certolizumab compared with placebo. The most common adverse reactions (≥7%) are upper respiratory tract infection, rash and urinary tract infection.

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsDrug Updates Tagged with:adalimumabapremilastbrodalumabCertolizumab Pegoletanerceptguselkumabguttate psoriasisinfliximabinverse psoriasisixekizumabPsoriatic Arthritispsoriatic erythrodermapustular psoriasisRheumatic Drugs at a Glancesecukinumabtildrakizumabustekinumabvulgar psoriasis

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    April 15, 2019

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Andrew Brookes / Image Source on Offset

    Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

    February 10, 2022

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences